other material
confidence high
sentiment positive
materiality 0.75
Incannex reports >$70M cash, two positive Phase 2 readouts, FDA Fast Track; outlines 2026 outlook
Incannex Healthcare Inc.
- Cash and cash equivalents >$70M, providing operating runway into 2027.
- IHL-42X (OSA) Phase 2 RePOSA: up to 83% AHI reduction; FDA Fast Track designation.
- PSX-001 (GAD) Phase 2: statistically significant improvement on HAM-A vs placebo.
- Completed $12.5M private placement; eliminated all Series A warrants.
- Authorized $20M share repurchase program.